Predictors of retention in methadone programs: A signal detection analysis

Drug and Alcohol Dependence

Volumn 83, Issue 3, 2006, Pages 218-224

  Villafranca, Steven W ^a   McKellar, John D ^a   Trafton, Jodie A ^a   Humphreys, Keith ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Methadone; Retention; Signal detection

Indexed keywords

LEVACETYLMETHADOL; METHADONE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG DEPENDENCE TREATMENT; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PATIENT COMPLIANCE; PATIENT SATISFACTION; PREDICTION; PRIORITY JOURNAL; SIGNAL DETECTION; STATISTICAL SIGNIFICANCE; VETERAN;

ADULT; CALIFORNIA; COMBINED MODALITY THERAPY; COMORBIDITY; COUNSELING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEALTH SERVICES RESEARCH; HEROIN DEPENDENCE; HIV INFECTIONS; HUMANS; MALE; METHADONE; METHADYL ACETATE; MIDDLE AGED; NARCOTICS; PATIENT DROPOUTS; PATIENT SATISFACTION; RISK-TAKING; SOCIOECONOMIC FACTORS; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; VETERANS;

EID: 33747005681     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2005.11.020     Document Type: Article

References (59)

1. Aday L., and Anderson R.A. A framework for the study of access to medical care. Health Serv. Res. 9 (1974) 208-220
2. Aday L., Begley C.E., Lairson D.R., Slater C.H., Richard A.J., and Montoya I.D. A framework for assessing the effectiveness, efficiency, and equity of behavioral health care. Am. J. Manag. Care 5 (1999) S25-S44
3. Anderson R.A., and Newman J.P. Societal and individual determinants of medical utilization in the United States. Milbank Q. 51 (1973) 95-124
4. Anderson R.A. Revisiting the behavioral model and access to medical care: does it matter?. J. Health Soc. Behav. 16 (1995) 1-10
5. Babst D.V., Chambers C.D., and Warner A. Patient characteristics associated with retention in a methadone maintenance program. Br. J. Addict. 66 (1971) 195-204
6. Ball J.C., Lange W.R., Myers C.P., and Friedman S.R. Reducing the risk of AIDS through methadone maintenance treatment. J. Health Soc. Behav. 29 (1988) 214-226
7. Beckman L.J., and Kocel K.M. The treatment delivery system and alcohol abuse in women: social policy implications. J. Soc. Issues 38 (1982) 139-151
8. Caplehorn J.R.M., and Bell J. Methadone dosage and retention of patients in maintenance treatment. Med. J. Aust. 154 (1991) 195-199
9. Caplehorn J.R.M., Dalton M.S.Y.N., Haldar F., Petrenas A.M., and Nisbet J.G. Methadone maintenance and addicts' risk of fatal heroin overdose. Subst. Use Misuse 31 (1996) 177-196
10. Caplehorn J.R.M., Lumley T.S., and Irwig L. Staff attitudes and retention of patients in methadone maintenance programs. Drug Alcohol Depend. 52 (1998) 57-61
11. Cohen J. Statistical Power Analysis for the Behavioral Sciences. second ed. (1988), Eribaum, Hillsdale, NJ
12. Condelli W.S. Strategies for increasing retention in methadone programs. J. Psychoactive Drugs 25 (1993) 143-147
13. Davoli M., Perucci C.A., Forastiere F., Doyle P., Rapiti E., and Zaccarelli M. Risk factors for overdose mortality: a case-control study within a cohort of intravenous drug users. Int. J. Epidemiol. 22 (1993) 273-277
14. De Leon G. Retention in drug-free therapeutic communities. NIDA Res. Monogr. 106 (1991) 218-244
15. Del Rio M., Mino A., and Perneger T.V. Predictors of patient retention in a newly established methadone maintenance treatment programme. Addiction 92 (1997) 1353-1360
16. Department of Veterans Affairs/Department of Defense. Management of Substance Use Disorder in the Primary Care Setting (2001), US Government Printing Office, Washington, DC
17. D'Ippoliti D., Davoli M., Perucci C.A., Pasqualini F., and Bargagli A.M. Retention in treatment of heroin users in Italy: the role of treatment type and of methadone maintenance dosage. Drug Alcohol Depend. 52 (1998) 167-171
18. Faggiano, F., Vigna-Taglianti, F., Versino, E., Lemma, P., 2003. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst. Rev. 3.
19. Gerstein, D.R., Johnson, R.A., Harwood, H.J., Fountain, D., Suter, N., Malloy, K., 1994. Evaluating Recovery Services: The California Drug and Alcohol Treatment Assessment (CALDATA). California Department of Alcohol and Drug Programs, Sacramento.
20. Greenfield, L., 1999. Methadone treatment outcomes in the National Treatment Improvement Evaluation Study (NTIES). Substance Abuse and Mental Health Services Administration. Bethesda, MD, USA.
21. Health Care Financing Administration, 1991. The International Classification of Diseases, 9th Revision, Clinical IV US Government Printing Office.
22. Hubbard R.L., Marsden M.E., Rachal J.V., Harwood H.J., Cavanaugh E.R., and Ginzburg H.M. Drug Abuse Treatment-A National Study of Effectiveness (1989), University of North Carolina Press, Chapel Hill
23. Humphreys, K., Trafton, J.A., Barnett, P. 2003. Clinical Practices and Outcomes in VA methadone Programs: Final Report. Department of Veterans Affairs. Washington DC, USA.
24. Joe G.W., Simpson D.D., and Hubbard R.L. Treatment predictors of tenure in methadone maintenance. J. Subst. Abuse 3 (1991) 73-84
25. Johnson R.E., Chutuape M.A., Strain E.C., Walsh S.L., Stitzer M.L., and Bigelow G.E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N. Engl. J. Med. 343 (2000) 1290-1297
26. Kazis L.E., Ren X.S., Lee A., Skinner K., Rogers W., Clark J., and Miller D.R. Health status in VA patients: results from the Veterans Health Study. Am. J. Med. Qual. 14 (1999) 28-38
27. Kiernan M., King A.C., Kraemer H.C., Stefanick M.L., and Killen J.D. Characteristics of successful and unsuccessful dieters: an application of signal detection methodology. Ann. Behav. Med. 20 (1998) 1-6
28. Kiernan M., Kraemer H.C., Winkleby M.A., King A.C., and Taylor C.B. Do logistic regression and signal detection identify different subgroups at risk? Implications for the design of tailored interventions. Psychol. Methods 6 (2001) 35-48
29. Killen J.D., Fortmann S.P., Kraemer H.C., Varady A., and Newman B. Who will relapse? Symptoms of nicotine dependence predict long-term relapse after smoking cessation. J. Consult. Clin. Psychol. 60 (1992) 797-801
30. King A.C., Kiernan M., Oman R.G., Kraemer H.C., Hull M., and Ahn D. Can we identify who will adhere to long-term physical activity? Signal detection methodology as a potential aid to clinical decision making. Health Psychol. 16 (1997) 380-389
31. Kraemer H.C. Evaluating Medical Tests: Objective and Quantitative Guidelines (1992), Sage, Newbury Park
32. Larsen D.L., Attkisson C.C., Hargreaves W.A., and Nguyen T.D. Assessment of client/patient satisfaction: development of a general scale. Eval. Program Plann. 2 (1979) 197-207
33. Marlatt G.A., Tucker J.A., Donovan D.M., and Vuchinich R.E. Help-seeking by substance abusers: the role of harm reduction and behavioral-economic approaches to facilitate treatment entry and retention. NIDA Res. Monogr. 165 (1997) 44-84
34. Marsch L.A. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta analysis. Addiction 93 (1998) 515-532
35. McGee D., Reed D., and Yano K. The results of logistic analyses when the variables are ghighly correlated: an empirical example using diet and CHD incidence. J. Chronic Dis. 37 (1984) 713-719
36. McLellan A.T. Patient characteristics associated with outcome. In: Cooper J.R., Altman F., Brown B.S., and Czechowicz D. (Eds). Research on the Treatment of Narcotic Addiction: State of the Art (1983), US Government Printing Office, Washington, DC 500-529
37. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., Pettinati H., and Argeriou M. The fifth edition of the Addiction Severity Index. J. Subst. Abuse Treat. 9 (1992) 199-213
38. McLellan A.T., Arndt I.O., Metzger D.S., Woody G.E., and O'Brien C.P. The effects of psychosocial services in substance abuse treatment. JAMA 269 (1993) 1953-1959
39. Mertens J.R., and Weisner C.M. Predictors of substance abuse treatment retention among women and men in an HMO. Alcohol Clin. Exp. Res. 24 (2000) 1525-1533
40. Metzger D.S., Woody G.E., McLellan A.T., O'Brien C.P., Druley P., Navaline H., DePhillippis D., Stolley P., and Abrutyn E. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospetive follow-up. J. Acquir. Immune Defic. Syndr. 6 (1993) 1049-1056
41. Newman R.G., and Whitehall W.B. Double-blind comparison of methadone and placebo-maintenance treatments of narcotic addicts in Hong Kong. Lancet 2 (1979) 485-488
42. NOVA Research Company 1989. Program Orientation Book for NIDA National AIDS Demonstration Research (NADR) Grantees and AIDS Targeted Outreach Program (ATOM) Contractors. NOVA Research Co., Bethesda.
43. Pani P.P., Pirastu R., Ricci A., and Gessa G.L. Prohibition of take-home dosages: negative consequences on methadone maintenance treatment. Drug Alcohol Depend. 41 (1996) 81-84
44. Phillips K.A., Morrison K.R., Anderson R.A., and Aday L.A. Understanding the context of healthcare utilization: assessing environmental and provider-related variables in the behavioral model of utilization. Health Serv. Res. 33 (1998) 571-596
45. Practice Guideline for the Treatment of Patients with Substance Use Disorders: Alcohol, Cocaine, Opioids, 1995. Am. J. Psychiatry. 152, S5-S59.
46. Preston K.L., Umbricht A., and Epstein D.H. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Arch. Gen. Psychiatry (2000) 395-404
47. Rabinowitz J., and Marjefsky S. Predictors of being expelled from and dropping out of alcohol treatment. Psychiatry Serv. 49 (1998) 187-189
48. Rhoades H.M., Creson D., Elk R., Schmitz J., and Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am. J. Public Health 88 (1998) 34-39
49. Saxon A.J., Wells E.A., Fleming C., Jackson T.R., and Calsyn D.A. Pre-treatment characteristics, program philosophy and level of ancillary services as predictors of methadone maintenance treatment outcome. Addiction 91 (1996) 1197-1209
50. Simpson D.D. The relation of time spent in drug abuse treatment to posttreatment outcome. Am. J. Psychiatry 136 (1979) 1449-1453
51. Simpson D.D. Treatment for drug abuse: follow-up outcomes and length of time spent. Arch. Gen. Psychiatry 38 (1981) 875-880
52. Simpson D.D., Joe G.W., and Brown B.S. Treatment retention and follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychol. Addict. Behav. 11 (1997) 294-307
53. Smith P.M., Kraemer H.C., Miller N.H., DeBusk R.F., and Taylor C.B. In-hospital smoking cessation programs: who responds, who doesn't. J. Consult. Clin. Psychol. 67 (1999) 19-27
54. Steer R.A. Osychosocial correlates of retention in methadone maintenance. Int. J. Addict. 15 (1980) 1003-1009
55. Stark M.J. Dropping out of substance abuse treatment: a clinically oriented review. Clin. Psychol. Rev. 12 (1992) 93-116
56. Strain E.C., Bigelow G.E., Liebson L.A., and Stitzer M.L. Moderate- vs. high-dose methadone in the treatment of opioid dependence. JAMA 281 (1999) 1000-1005
57. Torrens M., Castillo C., and Perez-Sola V. Retention in a low-threshold methadone maintenance program. Drug Alcohol Depend. 41 (1996) 55-59
58. Winkleby M.A., Flora J.A., and Kraemer H.C. A community-based heart disease intervention: predictors of change. Am. J. Public Health 84 (1994) 767-772
59. Zaric G.S., Barnett P.G., and Brandeau M.L. HIV transmission and the cost-effectiveness of methadone maintenance. Am. J. Public Health 90 (2000) 1100-1111